AKT 021
Alternative Names: AKT-021Latest Information Update: 16 Jan 2024
At a glance
- Originator Akthelia Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Wounds
Most Recent Events
- 31 Dec 2023 Akthelia Pharmaceuticals has patent protection for therapeutic platform technology, prior to December 2023 (Akthelia Pharmaceuticals website, December 2023)
- 11 Dec 2023 Preclinical trials in Wounds in Iceland (Topical), prior to December 2023 (Akthelia Pharmaceuticals pipeline, December 2023)